VYNE Therapeutics
VYNE
44 hedge funds and large institutions have $5.63M invested in VYNE Therapeutics in 2022 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 13 reducing their positions, and 17 closing their positions.
0.42% less ownership
Funds ownership: 1.27% → 0.86% (-0.42%)
19% less funds holding
Funds holding: 54 → 44 (-10)
54% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 13
55% less capital invested
Capital invested by funds: $12.5M → $5.63M (-$6.89M)
59% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 17
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Bailard
Foster City,
California
|
+$92K |
| 2 |
DA
DSC Advisors
Chicago,
Illinois
|
+$78.6K |
| 3 |
BPA
Beacon Pointe Advisors
Newport Beach,
California
|
+$49.5K |
| 4 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
+$43.1K |
| 5 |
Renaissance Technologies
New York
|
+$40K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$2.22M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$506K |
| 3 |
State Street
Boston,
Massachusetts
|
-$225K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$169K |
| 5 |
Goldman Sachs
New York
|
-$118K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Simplex Trading
Chicago,
Illinois
| – | -$1.29K | -109 | Closed |
|
|
SWM
52
Spire Wealth Management
Mclean,
Virginia
| – | -$2K | -109 | Closed |
|
53
Fidelity Investments
Boston,
Massachusetts
| – | -$2K | -83 | Closed |
|
|
MIFH
54
Migdal Insurance & Financial Holdings
Petach Tikva,
Israel
| – | -$1K | -59 | Closed |
|
55
Osaic Holdings
Scottsdale,
Arizona
| – | -$1K | -28 | Closed |
|
56
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$261 | -22 | -52% |
|
57
Rockefeller Capital Management
New York
| – | +$24 | +2 | +3% |
|
VYNE Hedge Fund Activity: Q1 2022 in Review
44 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q1 2022, worth a combined $5.63M — down 55% from $12.5M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of VYNE and 7 opened new positions — a net loss of 10 holders — while 13 trimmed existing stakes and 6 added.
The largest buyer was Bailard, opening a new position worth an estimated $92K. The largest seller was Perceptive Advisors, exiting entirely with an estimated $2.22M sold.
- 44 institutional investors held VYNE Therapeutics (VYNE) as of Q1 2022, down from 54 in Q4 2021.
- Funds reported $5.63M of VYNE Therapeutics stock for Q1 2022, down 55% quarter-over-quarter.
- 7 funds opened new VYNE Therapeutics positions in Q1 2022 and 17 closed out, a net change of -10 holders.
- The largest VYNE Therapeutics buyer in Q1 2022 was Bailard, an estimated $92K added.
- The largest VYNE Therapeutics seller in Q1 2022 was Perceptive Advisors, an estimated $2.22M sold.
Based on aggregated 13F filings for Q1 2022.